Tymora Analytical Operations is a leading brand that provides cutting-edge research products and reagents to R&D organizations in the life sciences market. At Tymora, our primary objective is to facilitate the transition from tissue to liquid biopsy, revolutionizing cancer research. We have developed state-of-the-art technologies that enable the direct detection of active exosome protein and phosphoprotein cancer markers from plasma, urine, or saliva.

This unique approach has immense potential for discovering, validating, and routinely detecting diagnostic markers that were previously inaccessible in biofluids. Our methodologies have gained international recognition for their novelty, effectiveness, and cost-efficiency in carrying out proteomic and phosphorylation analyses. Tymora has secured multiple NSF and NIH SBIR/STTR grants, allowing us to further develop our technologies for various applications.

We are actively seeking collaborations with partners interested in utilizing our technology for the design and validation of early disease detection tests, post-treatment cancer monitoring, and companion diagnostic assays for pipeline therapies. Trust Tymora Analytical to revolutionize cancer research through our innovative solutions and expertise. Together, let's pave the way for improved diagnostics and patient outcomes